CRISPR Therapeutics AG (NASDAQ:CRSP) has entered a $95 million upfront partnership with China-based Sirius Therapeutics to co ...

The gene editing company CRISPR Therapeutics surprisingly struck a deal with China-based biotech Sirius Therapeutics to ...

A new report concludes that mental health apps like Rejoyn and DaylightRx can save money and improve outcomes.

Tourmaline Bio disclosed results for a potential rival to a Novo Nordisk drug. Elsewhere, data emerged for a psychedelic and CRISPR Therapeutics expanded its toolkit.

NEW YORK – CRISPR Therapeutics and Sirius Therapeutics have inked a deal valued at up to $95 million to develop and commercialize small interfering RNA therapies, starting with a treatment for ...

Most of the 15 million children with a rare disease have no FDA-approved treatments available to them. And when it comes to ...

The partnership with Sirius expands CRISPR Therapeutics’ modality toolkit, especially in the cardiovascular space.

In the Phase 2 study of patients with chronic kidney disease, the highest dose of the drug lowered by 86% the levels of ...

Quantum computing has been lurking in the background for years. Discover 5 cutting-edge science sectors like CRISPR and ...

Swiss gene-editing specialist CRISPR Therapeutics (Nasdaq: CRSP) and San Diego, USA-based Sirius Therapeutics, which is ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

CRISPR Therapeutics is paying $25 million upfront to work on multiple siRNA targets with Sirius Tx with an early focus on the ...